ANTARES PHARMA INC (ATRS)
US0366421065 - Common Stock
| 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 65.91M | 53.10M | 23.20M | 27.90M | 26.60M | |||
| Marketable Securities | 1.25M | 0.00 | 22.50M | 0.00 | 5.00M | |||
| Receivables | 91.04M | 50.40M | 43.30M | 29.40M | 12.40M | |||
| Inventories | 11.54M | 18.20M | 16.00M | 11.40M | 9.30M | |||
| Other Current Assets | 4.53M | 4.90M | 3.40M | 2.60M | 2.30M | |||
| Total Current Assets | 174.27M | 126.60M | 108.40M | 71.30M | 55.50M | |||
| Non-Current Assets | ||||||||
| PPE Net | 29.79M | 28.60M | 21.40M | 14.90M | 16.20M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Intangibles | 17.88M | 7.70M | 500.00K | 800.00K | 1.40M | |||
| Other Non-Current Assets | 34.47M | 48.50M | 1.30M | 100.00K | 100.00K | |||
| Total Non-Current Assets | 83.23M | 85.90M | 24.40M | 17.00M | 18.80M | |||
| TOTAL ASSETS | 257.50M | 212.50M | 132.80M | 88.30M | 74.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 1.50M | 16.20M | 0.00 | 3.00M | N/A | |||
| Accrued Expenses | 27.11M | 17.20M | 14.90M | 3.70M | 2.50M | |||
| Accounts Payable | 17.06M | 16.20M | 12.90M | 11.10M | 6.00M | |||
| Other Current Liabilities | 13.26M | 13.60M | 4.60M | 9.30M | 7.30M | |||
| Total Current Liabilities | 58.93M | 63.20M | 32.40M | 27.20M | 15.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 18.24M | 24.70M | 40.40M | 22.10M | 24.90M | |||
| Other Non-Current Liabilities | 4.58M | 5.50M | 5.40M | 0.00 | 200.00K | |||
| Total Non-Current Liabilities | 22.82M | 30.20M | 45.90M | 22.10M | 25.10M | |||
| TOTAL LIABILITIES | 81.75M | 93.40M | 78.30M | 49.30M | 40.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -176.34M | -222.60M | -278.80M | -276.80M | -270.30M | |||
| Additional Paid In Capital | 351.08M | 340.80M | 332.40M | 314.90M | 303.00M | |||
| Common Shares | 1.70M | 1.70M | 1.70M | 1.60M | 1.60M | |||
| Other Shareholders' Equity | -690.00K | -700.00K | -700.00K | -700.00K | -700.00K | |||
| Shares Outstanding | 170.07M | 166.80M | 165.20M | 159.70M | 156.70M | |||
| Tangible Book Value per Share | 0.92 | 0.66 | 0.32 | 0.23 | 0.20 | |||
| Total Shareholders' Equity | 175.76M | 119.10M | 54.50M | 39.00M | 33.50M | |||
| TOTAL LIABILITIES AND EQUITY | 257.50M | 212.50M | 132.80M | 88.30M | 74.30M | |||
| Statistics | ||||||||
| Debt/Equity | 0.10 | 0.21 | 0.74 | 0.57 | 0.74 | |||
| Current Ratio | 2.96 | 2.00 | 3.35 | 2.62 | 3.54 | |||
| Return On Assets (ROA) | 17.98% | 26.45% | -1.51% | -7.36% | -22.48% | |||
| Return On Equity (ROE) | 26.34% | 47.19% | -3.67% | -16.67% | -49.85% | |||
| Return On Invested Capital (ROIC) | 10.88% | 7.20% | 0.79% | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | 16.44% | 11.17% | 1.44% | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 19.02% | 12.14% | 1.46% | N/A | N/A | |||
All data in USD